Author

Toby A Eyre

Department of Haematology, Oxford University Hospitals NHS Trust - Cited by 3,326 - Lymphoid Malignancy

Biography

Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust, specialising in the management of lymphoid malignancies. He is considered a national expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia. Dr. Eyre has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education.
Title
Cited by
Year
Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: additional patients and extended follow-up from the phase 1/2 BRUIN study
AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ...Blood 140 (Supplement 1), 2316-2320, 2022202
12
2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma
J Khwaja, AA Kirkwood, LK Isbell, S Steffanoni, H Goradia, L Pospiech, ...Haematologica 108 (3), 882, 202310202
10
2023
Efficacy of pirtobrutinib, a highly selective, non-covalent (Reversible) BTK Inhibitor in relapsed/refractory waldenström macroglobulinemia: results from the phase 1/2 BRUIN study
ML Palomba, MR Patel, TA Eyre, W Jurczak, DJ Lewis, T Gastinne, S Ma, ...Blood 140 (Supplement 1), 557-560, 2022202
10
2022
Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1/2 BRUIN study
WG Wierda, DJ Lewis, P Ghia, NN Shah, CC Coombs, CY Cheah, ...Blood 140 (Supplement 1), 846-84, 2022202
9
2022
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
C Rusconi, CY Cheah, TA Eyre, D Tucker, P Klener, E Giné, L Crucitti, ...Blood, The Journal of the American Society of Hematology 140 (1), 190-1916, 2022202
7
2022
Emerging therapies for the management of Richter transformation
E Smyth, TA Eyre, CY CheahJournal of Clinical Oncology 41 (2), 395-409, 2023202
7
2023
Efficacy of Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1/2 BRUIN study
ML Wang, NN Shah, W Jurczak, PL Zinzani, TA Eyre, CY Cheah, ...Blood 140 (Supplement 1), 9368-932, 2022202
7
2022
Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart …
G Hess, M Dreyling, L Oberic, E Gine, PL Zinzani, K Linton, A Vilmar, ...British Journal of Haematology, 2022202
5
2022
Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features
MS Davids, JP Sharman, TA Eyre, JA Woyach, PAP de Miranda, ...Blood 140 (Supplement 1), 4173-417, 2022202
5
2022
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
F Djebbari, M Poynton, G Sangha, L Anderson, R Maddams, TA Eyre, ...Hematology 27 (1), 20-207, 2022202
4
2022
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the …
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL inhibitor in the …TA Eyre, LM Hess, T Sugihara, D He, M Khanal, JM Pagel, RA Walgren, ...Leukemia & Lymphoma, 1-1, 030
2
2023
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma
BRUIN MCL-31: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphomaTA Eyre, NN Shah, M Dreyling, W Jurczak, Y Wang, CY Cheah, Y Song, ...Future Oncology 18 (36), 3961-3969, 0
2
2022
Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 …
Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/ …NN Shah, ML Wang, JR Brown, K Patel, JA Woyach, WG Wierda, ...Blood 140 (Supplement 1), 417-413, 0
2
2022
Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide
M Bishton, C Woestmann, F Morschhauser, TA Eyre, M Shin, A Schroeder, ...Blood 40 (Supplement ), 3555-3556, 2022202
1
2022
A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory …
G Hess, M Dreyling, L Oberic, E Gine, PL Zinzani, KM Linton, A Vilmar, ...Blood 40 (Supplement ), 0296-0299, 2022202
1
2022
First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory …
First-in-Human Phase I Trial of a ROR Targeting Bispecific T Cell Engager (NVG-) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory …W Townsend, S Leong, D Tucker, B Pottinger, S Paneesha, ...Blood 40 (Supplement ), 462-463, 2022202
1
2022
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ...New England Journal of Medicine 389 (), 33-44, 2023202
1
2023
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-9 pandemic: Initial results of a UK-wide real-world studyF Djebbari, A Rampotas, G Vallance, F Panitsas, N Basker, G Sangha, ...Hematology 27 (), 69-699, 2022202
1
2022
Impact of positron emission tomography-computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell …
TA Eyre, SF Barrington, J Okosun, C Abamba, RM Pearce, J Lee, ...Haematologica 08 (3), 785, 2023202
1
2023
Abstract CT167: Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1/2 BRUIN study
Abstract CT67: Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase /2 BRUIN studyJ Rhodes, D Lewis, P Ghia, NN Shah, CC Coombs, CY Cheah, J Woyach, ...Cancer Research 83 (8_Supplement), CT67-CT67, 2023202
1
2023

Referred From: https://scholar.google.co.uk/citations?user=Eok0DZkAAAAJ&hl=en

Cited by
Citations 3326
h-index 31
i10-index 88
Recommended Journals
Open Access Journals